A Phase 4 interventional study of Setmelanotide and Moxifloxacin in Healthy, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-03.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a double-blind, randomized, placebo- and positive-controlled, parallel group, 3-arm study that assessed the potential for therapeutic and supratherapeutic concentrations of setmelanotide to affect the QTc corrected by the Fredericia method (QTcF) interval.
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received titrated doses of 2-7 milligrams (mg) setmelanotide once daily by subcutaneous (SC) injection, starting with a dose of 2 mg from Days 1 to 7, 3 mg from Days 8 to 10, 5 mg from Days 11 to 13 and 7 mg from Days 14 to 16. Participants also received single oral dose of placebo matching moxifloxacin on Days 10 and 16.
Drug: Setmelanotide · Drug: Oral Placebo
Participants received placebo matching setmelanotide once daily by SC injection from Days 1 to 16. Participants also received a single oral dose of 400 mg moxifloxacin on Day 10 and a single oral dose of placebo matching moxifloxacin on Day 16.
Drug: Moxifloxacin · Drug: Oral Placebo · Drug: SC Placebo
Participants received placebo matching setmelanotide once daily by SC injection from Days 1 to 16. Participants also received a single oral dose of placebo matching moxifloxacin on Day 10 and a single oral dose of 400 mg moxifloxacin on Day 16.
Drug: Moxifloxacin · Drug: Oral Placebo · Drug: SC Placebo
Administered once daily via SC injection.
Moxifloxacin capsules via oral administration.
Placebo capsules via oral administration.
Placebo via SC injection.
Setmelanotide Concentration-related Placebo-corrected Change From Baseline (CHFB) in Fridericia's Correction (QTcF) at Day 10
Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Baseline and Day 10. ECG analysts were blinded to the treatment, timepoint and participant. QT interval was corrected for heart rate using QTcF. CHFB in QTcF was calculated at each timepoint.
Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hours (hrs) postdose
Setmelanotide Concentration-related Placebo-corrected CHFB in QTcF at Day 16
Continuous 12-lead digital ECG recording was performed on Baseline and Day 16. ECG analysts were blinded to the treatment, timepoint and participant. QT interval was corrected for heart rate using QTcF. CHFB in QTcF was calculated at each timepoint.
Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Placebo-corrected CHFB in Heart Rate (HR) After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10
The CHFB in HR was analyzed using an analysis of variance model (ANOVA) including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate. Placebo corrected values were reported in the inferential statistics.
Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hours (hrs) postdose
Placebo-corrected CHFB in HR After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16
The CHFB in HR was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Placebo-corrected CHFB in QTcF Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10
The CHFB in QTcF was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Placebo-corrected CHFB in QTcF Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16
The CHFB in QTcF was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Placebo-corrected CHFB in PR Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10
The CHFB in PR was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Placebo-corrected CHFB in PR Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16
The CHFB in PR was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Placebo-corrected CHFB in QRS Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10
The CHFB in QRS was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Placebo-corrected CHFB in QRS Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16
The CHFB in QRS was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Number of Participants With at Least One Treatment-Emergent Abnormal Value in HR Intervals After Administration of SC Setmelanotide
A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: HR (\<40 beats/min, HR\>120 beats/min and Relative CHFB \>25%) Relative CHFB = 100\*(Value-Baseline)/Baseline
Time frame: Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)
Number of Participants With at Least One Treatment-Emergent Abnormal Value in PR Intervals After Administration of SC Setmelanotide
A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: PR (\>220 msec, Relative CHFB \>25%); Relative CHFB = 100\*(Value-Baseline)/Baseline
Time frame: Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)
Number of Participants With at Least One Treatment-Emergent Abnormal Value in QRS Intervals After Administration of SC Setmelanotide
A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: QRS ( \>120 msec, Relative CHFB \>25%); Relative CHFB = 100\*(Value-Baseline)/Baseline
Time frame: Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)
Number of Participants With at Least One Treatment-Emergent Abnormal Value in QTcF Intervals After Administration of SC Setmelanotide
A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: QTcF (450\<QTc\<=480 msec, 480\<QTc\<=500 msec, QTc\>500 msec, 30\<CHFB in QTc\<=60 msec, CHFB in \>60 msec)
Time frame: Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)
Number of Participants With at Least One Treatment-Emergent Abnormal Finding in T-wave Morphology and U-wave Presence After Administration of SC Setmelanotide
A treatment-emergent abnormality/finding will be defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included : QTcF Increase From Baseline, \> 30 msec And \< 60 msec
Time frame: Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)
Moxifloxacin Concentration-related CHFB in QTcF at Day 10
Continuous 12-lead digital ECG recording was performed on Baseline and Day 10. ECG analysts were blinded to the treatment, timepoint and participant. CHFB in QTcF was calculated at each timepoint.
Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Moxifloxacin Concentration-related CHFB in QTcF at Day 16
Continuous 12-lead digital ECG recording was performed on Baseline and Day 16. ECG analysts were blinded to the treatment, timepoint and participant. CHFB in QTcF was calculated at each timepoint.
Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
77 healthy participants aged 18 to 50 years, inclusive, were enrolled in the United States.
| Milestone | Group 1: Setmelanotide 2-7 mg + Placebo for Moxifloxacin | Group 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for Moxifloxacin | Group 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mg |
|---|---|---|---|
| Started | 28 | 24 | 25 |
| Received 2 mg setmelanotide | 28 | 0 | 0 |
| Received 3 mg setmelanotide | 24 | 0 | 0 |
| Received 5 mg setmelanotide | 23 | 0 | 0 |
| Received 7 mg setmelanotide | 21 | 0 | 0 |
| Completed | 21 | 23 | 25 |
| Not completed | 7 | 1 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 |
| Withdrew: Positive covid19 result. | 0 | 1 | 0 |
Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Baseline and Day 10. ECG analysts were blinded to the treatment, timepoint and participant. QT interval was corrected for heart rate using QTcF. CHFB in QTcF was calculated at each timepoint.
| milliseconds (msec) | Group 1: Setmelanotide 3 mg | Group 3: Placebo |
|---|---|---|
| Predose | 1.9 ± 7.82 | -1.5 ± 5.25 |
| 0.5 hr Post dose | -3.6 ± 9.83 | -3.5 ± 8.16 |
| 1 hr Post dose | -2.9 ± 12.69 | -3.5 ± 5.87 |
| 1.5 hr Post dose | -3.0 ± 9.53 | -3.2 ± 7.44 |
| 2 hr Post dose | -1.0 ± 11.26 | -3.4 ± 5.70 |
| 2.5 hr Post dose | 1.2 ± 11.22 | -2.0 ± 8.92 |
| 3 hr Post dose | 2.1 ± 10.06 | -2.6 ± 6.75 |
| 4 hr Post dose | 2.0 ± 9.76 | -2.4 ± 8.09 |
| 5 hr Post dose | 2.4 ± 9.38 | 0.2 ± 8.99 |
| 6 hr Post dose | -0.4 ± 9.71 | -1.8 ± 6.88 |
| 7 hr Post dose | 1.0 ± 8.02 | -1.3 ± 7.36 |
| 8 hr Post dose | 2.6 ± 9.11 | -0.3 ± 7.93 |
| 9 hr Post dose | 4.1 ± 7.84 | -2.0 ± 6.58 |
| 10 hr Post dose | 5.0 ± 8.14 | -0.9 ± 9.96 |
| 12 hr Post dose | 1.9 ± 9.25 | 3.4 ± 8.65 |
| 16 hr Post dose | 1.7 ± 7.46 | -1.0 ± 7.64 |
| 24 hr Post dose | -0.7 ± 13.32 | 1.6 ± 8.28 |
Continuous 12-lead digital ECG recording was performed on Baseline and Day 16. ECG analysts were blinded to the treatment, timepoint and participant. QT interval was corrected for heart rate using QTcF. CHFB in QTcF was calculated at each timepoint.
| msec | Group 1: Setmelanotide 7 mg | Group 2: Placebo |
|---|---|---|
| Predose | 4.5 ± 6.49 | -2.3 ± 8.24 |
| 0.5 hr Post dose | 1.0 ± 8.83 | -5.2 ± 6.97 |
| 1 hr Post dose | 1.6 ± 9.18 | -4.3 ± 8.20 |
| 1.5 hr Post dose | 0.3 ± 10.42 | -2.9 ± 8.64 |
| 2 hr Post dose | 2.2 ± 10.94 | -2.0 ± 8.96 |
| 2.5 hr Post dose | 2.7 ± 11.61 | -2.5 ± 9.09 |
| 3 hr Post dose | 4.3 ± 11.34 | -2.0 ± 8.07 |
| 4 hr Post dose | 3.6 ± 9.88 | -2.5 ± 6.37 |
| 5 hr Post dose | 4.7 ± 9.41 | -0.5 ± 6.42 |
| 6 hr Post dose | 2.8 ± 9.64 | -2.4 ± 7.28 |
| 7 hr Post dose | 1.5 ± 11.14 | -2.0 ± 6.31 |
| 8 hr Post dose | 2.8 ± 10.02 | -2.6 ± 8.27 |
| 9 hr Post dose | 6.1 ± 8.72 | -1.2 ± 7.00 |
| 10 hr Post dose | 6.5 ± 6.64 | -2.5 ± 7.14 |
| 12 hr Post dose | 5.8 ± 7.96 | -0.4 ± 5.99 |
| 16 hr Post dose | 1.4 ± 7.77 | -2.6 ± 9.30 |
| 24 hr Post dose | 1.0 ± 11.26 | -5.6 ± 9.67 |
The CHFB in HR was analyzed using an analysis of variance model (ANOVA) including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate. Placebo corrected values were reported in the inferential statistics.
| beats per minute (bpm) | Group 1: Setmelanotide 3 mg | Group 2: Moxifloxacin 400 mg |
|---|---|---|
| Pre dose | 2.3 ± 9.65 | -0.3 ± 7.31 |
| 0.5 hr Post dose | -2.0 ± 9.58 | 0.9 ± 6.39 |
| 1 hr Post dose | -2.7 ± 11.67 | 1.3 ± 5.79 |
| 1.5 hr Post dose | -0.2 ± 13.13 | 2.0 ± 5.51 |
| 2 hr Post dose | -2.1 ± 10.94 | 0.0 ± 6.77 |
| 2.5 hr Post dose | -1.8 ± 9.31 | 1.7 ± 6.33 |
| 3 hr Post dose | 0.2 ± 10.70 | -0.4 ± 8.47 |
| 4 hr Post dose | -1.2 ± 7.91 | -0.6 ± 6.26 |
| 5 hr Post dose | 0.6 ± 7.51 | 3.1 ± 7.36 |
| 6 hr Post dose | -1.3 ± 7.66 | 3.6 ± 5.97 |
| 7 hr Post dose | -2.9 ± 6.45 | 0.9 ± 4.74 |
| 8 hr Post dose | -2.2 ± 5.93 | 2.4 ± 7.04 |
| 9 hr Post dose | -1.3 ± 6.34 | 1.3 ± 6.27 |
| 10 hr Post dose | -0.8 ± 5.82 | 0.9 ± 5.33 |
| 12 hr Post dose | -2.8 ± 7.49 | 3.3 ± 6.03 |
| 16 hr Post dose | 1.7 ± 6.93 | 1.9 ± 7.00 |
| 24 hr Post dose | 2.1 ± 6.04 | 1.3 ± 5.37 |
The CHFB in HR was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
| bpm | Group 1: Setmelanotide 7 mg | Group 3: Moxifloxacin 400 mg |
|---|---|---|
| Pre dose | 3.4 ± 7.41 | -0.3 ± 4.95 |
| 0.5 hr Post dose | -1.7 ± 9.57 | -0.1 ± 6.35 |
| 1 hr Post dose | -2.2 ± 10.61 | 0.1 ± 5.96 |
| 1.5 hr Post dose | -1.5 ± 10.35 | 1.5 ± 5.78 |
| 2 hr Post dose | -3.0 ± 7.19 | 0.5 ± 5.14 |
| 2.5 hr Post dose | -0.8 ± 7.24 | 0.4 ± 6.49 |
| 3 hr Post dose | -0.2 ± 7.11 | 2.1 ± 5.44 |
| 4 hr Post dose | 1.5 ± 6.90 | 2.0 ± 5.18 |
| 5 hr Post dose | 3.5 ± 7.84 | 3.4 ± 5.76 |
| 6 hr Post dose | 3.9 ± 9.21 | 0.7 ± 5.66 |
| 7 hr Post dose | 1.2 ± 6.71 | 3.3 ± 7.68 |
| 8 hr Post dose | 0.8 ± 7.13 | 2.8 ± 4.71 |
| 9 hr Post dose | 1.5 ± 7.30 | 1.6 ± 6.59 |
| 10 hr Post dose | 2.1 ± 7.82 | 2.8 ± 5.16 |
| 12 hr Post dose | 0.6 ± 8.00 | 3.0 ± 3.86 |
| 16 hr Post dose | 3.0 ± 6.98 | 3.3 ± 4.75 |
| 24 hr Post dose | 6.2 ± 7.41 | 0.4 ± 6.39 |
The CHFB in QTcF was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
| msec | Group 1: Setmelanotide 3 mg | Group 2: Moxifloxacin 400 mg |
|---|---|---|
| Pre dose | 1.9 ± 7.82 | 1.5 ± 7.76 |
| 0.5 hr Post dose | -3.6 ± 9.83 | -5.3 ± 8.75 |
| 1 hr Post dose | -2.9 ± 12.69 | -3.7 ± 9.39 |
| 1.5 hr Post dose | -3.0 ± 9.53 | 0.9 ± 8.56 |
| 2 hr Post dose | -1.0 ± 11.26 | 2.0 ± 8.74 |
| 2.5 hr Post dose | 1.2 ± 11.22 | 4.9 ± 8.75 |
| 3 hr Post dose | 2.1 ± 10.06 | 4.9 ± 7.39 |
| 4 hr Post dose | 2.0 ± 9.76 | 6.3 ± 8.63 |
| 5 hr Post dose | 2.4 ± 9.38 | 8.1 ± 8.42 |
| 6 hr Post dose | -0.4 ± 9.71 | 6.0 ± 6.61 |
| 7 hr Post dose | 1.0 ± 8.02 | 5.1 ± 8.39 |
| 8 hr Post dose | 2.6 ± 9.11 | 4.4 ± 8.18 |
| 9 hr Post dose | 4.1 ± 7.84 | 5.0 ± 10.47 |
| 10 hr Post dose | 5.0 ± 8.14 | 6.2 ± 6.85 |
| 12 hr Post dose | 1.9 ± 9.25 | 8.7 ± 4.84 |
| 16 hr Post dose | 1.7 ± 7.46 | 5.9 ± 8.09 |
| 24 hr Post dose | -0.7 ± 13.32 | 6.6 ± 8.00 |
The CHFB in QTcF was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
| msec | Group 1: Setmelanotide 7 mg | Group 3: Moxifloxacin 400 mg |
|---|---|---|
| Pre dose | 4.5 ± 6.49 | -0.8 ± 8.30 |
| 0.5 hr Post dose | 1.0 ± 8.83 | -1.8 ± 5.93 |
| 1 hr Post dose | 1.6 ± 9.18 | -1.9 ± 7.49 |
| 1.5 hr Post dose | 0.3 ± 10.42 | 3.0 ± 7.05 |
| 2 hr Post dose | 2.2 ± 10.94 | 4.2 ± 7.53 |
| 2.5 hr Post dose | 2.7 ± 11.61 | 7.6 ± 8.45 |
| 3 hr Post dose | 4.3 ± 11.34 | 8.1 ± 8.19 |
| 4 hr Post dose | 3.6 ± 9.88 | 8.8 ± 6.37 |
| 5 hr Post dose | 4.7 ± 9.41 | 7.5 ± 8.97 |
| 6 hr Post dose | 2.8 ± 9.64 | 8.5 ± 6.18 |
| 7 hr Post dose | 1.5 ± 11.14 | 9.1 ± 7.29 |
| 8 hr Post dose | 2.8 ± 10.02 | 8.0 ± 5.73 |
| 9 hr Post dose | 6.1 ± 8.72 | 7.0 ± 7.33 |
| 10 hr Post dose | 6.5 ± 6.64 | 7.0 ± 9.93 |
| 12 hr Post dose | 5.8 ± 7.96 | 10.8 ± 9.14 |
| 16 hr Post dose | 1.4 ± 7.77 | 6.6 ± 8.51 |
| 24 hr Post dose | 1.0 ± 11.26 | 4.4 ± 10.57 |
The CHFB in PR was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
| msec | Group 1: Setmelanotide 3 mg | Group 2: Moxifloxacin 400 mg |
|---|---|---|
| Pre dose | -2.4 ± 6.12 | 3.1 ± 5.18 |
| 0.5 hr Post dose | -3.8 ± 8.93 | 3.4 ± 8.29 |
| 1 hr Post dose | -1.0 ± 6.22 | 3.5 ± 7.33 |
| 1.5 hr Post dose | -1.0 ± 6.24 | 3.7 ± 7.04 |
| 2 hr Post dose | -1.0 ± 6.98 | 3.3 ± 7.44 |
| 2.5 hr Post dose | -3.1 ± 4.92 | 1.5 ± 6.53 |
| 3 hr Post dose | -3.9 ± 7.81 | 2.6 ± 6.76 |
| 4 hr Post dose | -1.2 ± 5.78 | 1.6 ± 8.41 |
| 5 hr Post dose | -1.0 ± 6.61 | 0.5 ± 5.46 |
| 6 hr Post dose | -1.7 ± 5.87 | -0.2 ± 6.62 |
| 7 hr Post dose | -2.5 ± 4.88 | 0.3 ± 5.06 |
| 8 hr Post dose | -1.9 ± 7.06 | 0.3 ± 7.37 |
| 9 hr Post dose | -2.3 ± 6.03 | 0.5 ± 4.49 |
| 10 hr Post dose | -1.2 ± 7.06 | -0.8 ± 6.30 |
| 12 hr Post dose | -3.9 ± 7.83 | -2.1 ± 6.05 |
| 16 hr Post dose | -3.0 ± 7.02 | -0.0 ± 7.24 |
| 24 hr Post dose | -6.6 ± 8.39 | 1.2 ± 5.65 |
The CHFB in PR was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
| msec | Group 1: Setmelanotide 7 mg | Group 3: Moxifloxacin 400 mg |
|---|---|---|
| Pre dose | -3.5 ± 7.11 | 3.4 ± 11.46 |
| 0.5 hr Post dose | -4.5 ± 11.01 | 3.9 ± 9.88 |
| 1 hr Post dose | 0.4 ± 7.72 | 5.8 ± 10.90 |
| 1.5 hr Post dose | -2.3 ± 7.45 | 2.4 ± 9.42 |
| 2 hr Post dose | 0.1 ± 6.67 | 2.0 ± 8.17 |
| 2.5 hr Post dose | -0.9 ± 7.36 | 3.2 ± 7.46 |
| 3 hr Post dose | -2.2 ± 7.12 | 2.0 ± 8.00 |
| 4 hr Post dose | -1.3 ± 6.34 | 1.3 ± 9.51 |
| 5 hr Post dose | -2.6 ± 6.70 | 1.2 ± 9.99 |
| 6 hr Post dose | -1.7 ± 7.99 | 0.7 ± 8.87 |
| 7 hr Post dose | -3.7 ± 5.65 | -1.1 ± 9.29 |
| 8 hr Post dose | -3.1 ± 5.97 | 0.8 ± 8.52 |
| 9 hr Post dose | -3.4 ± 5.08 | 0.4 ± 7.66 |
| 10 hr Post dose | -1.4 ± 6.36 | 1.1 ± 7.80 |
| 12 hr Post dose | -1.9 ± 5.77 | 0.8 ± 7.27 |
| 16 hr Post dose | -4.9 ± 6.64 | 0.9 ± 8.78 |
| 24 hr Post dose | -8.4 ± 9.21 | 2.5 ± 7.28 |
The CHFB in QRS was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
| msec | Group 1: Setmelanotide 3 mg | Group 2: Moxifloxacin 400 mg |
|---|---|---|
| Pre dose | -0.2 ± 4.90 | 0.9 ± 3.42 |
| 0.5 hr Post dose | 0.0 ± 3.85 | 0.6 ± 6.31 |
| 1 hr Post dose | 0.5 ± 5.21 | 0.8 ± 3.38 |
| 1.5 hr Post dose | -0.6 ± 3.69 | -0.2 ± 3.06 |
| 2 hr Post dose | 0.2 ± 4.04 | 0.1 ± 3.37 |
| 2.5 hr Post dose | 0.2 ± 4.41 | 0.5 ± 4.70 |
| 3 hr Post dose | 0.7 ± 4.31 | 0.4 ± 3.60 |
| 4 hr Post dose | 0.6 ± 3.95 | -0.7 ± 3.94 |
| 5 hr Post dose | 0.5 ± 3.82 | 1.0 ± 3.88 |
| 6 hr Post dose | 0.4 ± 4.71 | -0.4 ± 3.92 |
| 7 hr Post dose | 0.9 ± 5.30 | 0.1 ± 3.66 |
| 8 hr Post dose | 0.2 ± 4.23 | 1.1 ± 3.85 |
| 9 hr Post dose | -0.2 ± 4.19 | -0.1 ± 2.93 |
| 10 hr Post dose | 1.6 ± 4.23 | 0.2 ± 3.95 |
| 12 hr Post dose | 0.8 ± 5.08 | 1.9 ± 4.10 |
| 16 hr Post dose | 1.0 ± 4.77 | 1.5 ± 3.97 |
| 24 hr Post dose | -0.3 ± 5.38 | 1.6 ± 4.53 |
The CHFB in QRS was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.
| msec | Group 1: Setmelanotide 7 mg | Group 3: Moxifloxacin 400 mg |
|---|---|---|
| Pre dose | 1.0 ± 4.11 | -0.8 ± 3.90 |
| 0.5 hr Post dose | 0.5 ± 3.57 | 0.2 ± 3.90 |
| 1 hr Post dose | 0.9 ± 3.20 | -1.0 ± 6.86 |
| 1.5 hr Post dose | -0.8 ± 3.06 | -0.4 ± 3.65 |
| 2 hr Post dose | -0.2 ± 3.97 | 0.3 ± 3.41 |
| 2.5 hr Post dose | 1.1 ± 2.95 | -0.2 ± 4.20 |
| 3 hr Post dose | 0.5 ± 2.91 | 1.0 ± 3.69 |
| 4 hr Post dose | 0.7 ± 4.35 | 0.5 ± 2.93 |
| 5 hr Post dose | -0.2 ± 4.31 | -1.4 ± 5.54 |
| 6 hr Post dose | -0.2 ± 4.63 | 0.3 ± 2.99 |
| 7 hr Post dose | 1.5 ± 4.92 | 0.7 ± 4.10 |
| 8 hr Post dose | -0.2 ± 4.03 | 0.7 ± 2.77 |
| 9 hr Post dose | 0.2 ± 4.13 | -0.4 ± 3.15 |
| 10 hr Post dose | 1.2 ± 3.19 | -1.2 ± 2.73 |
| 12 hr Post dose | 1.4 ± 5.13 | -0.2 ± 4.74 |
| 16 hr Post dose | 1.1 ± 2.90 | -0.7 ± 4.75 |
| 24 hr Post dose | 1.3 ± 4.68 | 0.5 ± 3.69 |
A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: HR (\<40 beats/min, HR\>120 beats/min and Relative CHFB \>25%) Relative CHFB = 100\*(Value-Baseline)/Baseline
| Participants | Group 1: Setmelanotide 3 mg | Group 1: Setmelanotide 7 mg |
|---|---|---|
| HR<40 beats/min | 0 | 0 |
| HR>120 beats/min | 0 | 0 |
| Relative CHFB in HR>25% | 4 | 9 |
A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: PR (\>220 msec, Relative CHFB \>25%); Relative CHFB = 100\*(Value-Baseline)/Baseline
| Participants | Group 1: Setmelanotide 3 mg | Group 1: Setmelanotide 7 mg |
|---|---|---|
| PR>220 msec | 0 | 0 |
| Relative CHFB in PR>25% | 0 | 0 |
A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: QRS ( \>120 msec, Relative CHFB \>25%); Relative CHFB = 100\*(Value-Baseline)/Baseline
| Participants | Group 1: Setmelanotide 3 mg | Group 1: Setmelanotide 7 mg |
|---|---|---|
| QRS>120 msec | 0 | 0 |
| Relative CHFB in QRS>25% | 0 | 0 |
A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: QTcF (450\<QTc\<=480 msec, 480\<QTc\<=500 msec, QTc\>500 msec, 30\<CHFB in QTc\<=60 msec, CHFB in \>60 msec)
| Participants | Group 1: Setmelanotide 3 mg | Group 1: Setmelanotide 7 mg |
|---|---|---|
| 450<QTc<=480 msec | 0 | 0 |
| 480<QTc<=500 msec | 0 | 0 |
| QTc>500 msec | 0 | 0 |
| 30<CHFB in QTc<=60 msec | 0 | 0 |
| CHFB in QTc>60 msec | 0 | 0 |
A treatment-emergent abnormality/finding will be defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included : QTcF Increase From Baseline, \> 30 msec And \< 60 msec
| Participants | Group 1: Setmelanotide 3 mg | Group 1: Setmelanotide 7 mg |
|---|---|---|
| Number of Participants With at Least One Treatment-Emergent Abnormal Finding in T-wave Morphology and U-wave Presence After Administration of SC Setmelanotide | 1 | 1 |
Continuous 12-lead digital ECG recording was performed on Baseline and Day 10. ECG analysts were blinded to the treatment, timepoint and participant. CHFB in QTcF was calculated at each timepoint.
| msec | Group 2: Moxifloxacin 400 mg |
|---|---|
| Pre dose | 1.5 ± 7.76 |
| 0.5 hr Post dose | -5.3 ± 8.75 |
| 1 hr Post dose | -3.7 ± 9.39 |
| 1.5 hr Post dose | 0.9 ± 8.56 |
| 2 hr Post dose | 2.0 ± 8.74 |
| 2.5 hr Post dose | 4.9 ± 8.75 |
| 3 hr Post dose | 4.9 ± 7.39 |
| 4 hr Post dose | 6.3 ± 8.63 |
| 5 hr Post dose | 8.1 ± 8.42 |
| 6 hr Post dose | 6.0 ± 6.61 |
| 7 hr Post dose | 5.1 ± 8.39 |
| 8 hr Post dose | 4.4 ± 8.18 |
| 9 hr Post dose | 5.0 ± 10.47 |
| 10 hr Post dose | 6.2 ± 6.85 |
| 12 hr Post dose | 8.7 ± 4.84 |
| 16 hr Post dose | 5.9 ± 8.09 |
| 24 hr Post dose | 6.6 ± 8.00 |
Continuous 12-lead digital ECG recording was performed on Baseline and Day 16. ECG analysts were blinded to the treatment, timepoint and participant. CHFB in QTcF was calculated at each timepoint.
| msec | Group 3: Moxifloxacin 400 mg |
|---|---|
| Pre dose | -0.8 ± 8.30 |
| 0.5 hr Post dose | -1.8 ± 5.93 |
| 1 hr Post dose | -1.9 ± 7.49 |
| 1.5 hr Post dose | 3.0 ± 7.05 |
| 2 hr Post dose | 4.2 ± 7.53 |
| 2.5 hr Post dose | 7.6 ± 8.45 |
| 3 hr Post dose | 8.1 ± 8.19 |
| 4 hr Post dose | 8.8 ± 6.37 |
| 5 hr Post dose | 7.5 ± 8.97 |
| 6 hr Post dose | 8.5 ± 6.18 |
| 7 hr Post dose | 9.1 ± 7.29 |
| 8 hr Post dose | 8.0 ± 5.73 |
| 9 hr Post dose | 7.0 ± 7.33 |
| 10 hr Post dose | 7.0 ± 9.93 |
| 12 hr Post dose | 10.8 ± 9.14 |
| 16 hr Post dose | 6.6 ± 8.51 |
| 24 hr Post dose | 4.4 ± 10.57 |
Collected over From first dose up to Day 23. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Setmelanotide 2 mg | 0/28 (0%) | 1/28 (3.6%) | 25/28 (89.3%) |
| Group 1: Setmelanotide 3 mg | 0/24 (0%) | 0/24 (0%) | 16/24 (66.7%) |
| Group 1: Setmelanotide 5 mg | 0/23 (0%) | 0/23 (0%) | 17/23 (73.9%) |
| Group 1: Setmelanotide 7 mg | 0/21 (0%) | 0/21 (0%) | 9/21 (42.9%) |
| Group 2: Placebo | 0/24 (0%) | 0/24 (0%) | 18/24 (75%) |
| Group 2: Moxifloxacin 400mg | 0/23 (0%) | 0/23 (0%) | 17/23 (73.9%) |
| Group 3: Placebo | 0/25 (0%) | 0/25 (0%) | 15/25 (60%) |
| Group 3: Moxifloxacin 400mg | 0/25 (0%) | 0/25 (0%) | 4/25 (16%) |
| Event | Group 1: Setmelanotide 2 mg | Group 1: Setmelanotide 3 mg | Group 1: Setmelanotide 5 mg | Group 1: Setmelanotide 7 mg | Group 2: Placebo | Group 2: Moxifloxacin 400mg | Group 3: Placebo | Group 3: Moxifloxacin 400mg |
|---|---|---|---|---|---|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 1/28 | 0/24 | 0/23 | 0/21 | 0/24 | 0/23 | 0/25 | 0/25 |
| Hepatitis acuteHepatobiliary disorders | 1/28 | 0/24 | 0/23 | 0/21 | 0/24 | 0/23 | 0/25 | 0/25 |
| Event | Group 1: Setmelanotide 2 mg | Group 1: Setmelanotide 3 mg | Group 1: Setmelanotide 5 mg | Group 1: Setmelanotide 7 mg | Group 2: Placebo | Group 2: Moxifloxacin 400mg | Group 3: Placebo | Group 3: Moxifloxacin 400mg |
|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 11/28 | 7/24 | 6/23 | 7/21 | 8/24 | 12/23 | 11/25 | 0/25 |
| NauseaGastrointestinal disorders | 13/28 | 0/24 | 4/23 | 2/21 | 1/24 | 0/23 | 0/25 | 2/25 |
| Injection site erythemaGeneral disorders | 7/28 | 10/24 | 7/23 | 2/21 | 1/24 | 6/23 | 6/25 | 0/25 |
| Injection site swellingGeneral disorders | 4/28 | 1/24 | 3/23 | 4/21 | 1/24 | 4/23 | 9/25 | 0/25 |
| VomitingGastrointestinal disorders | 8/28 | 0/24 | 1/23 | 1/21 | 1/24 | 0/23 | 0/25 | 0/25 |
| EphelidesSkin and subcutaneous tissue disorders | 6/28 | 1/24 | 0/23 | 0/21 | 0/24 | 0/23 | 1/25 | 0/25 |
| Decreased appetiteMetabolism and nutrition disorders | 6/28 | 0/24 | 2/23 | 0/21 | 0/24 | 0/23 | 0/25 | 0/25 |
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 5/28 | 2/24 | 0/23 | 1/21 | 2/24 | 0/23 | 0/25 | 0/25 |
| Injection site pruritusGeneral disorders | 3/28 | 4/24 | 3/23 | 1/21 | 3/24 | 1/23 | 4/25 | 0/25 |
| HeadacheNervous system disorders | 4/28 | 0/24 | 1/23 | 1/21 | 2/24 | 0/23 | 1/25 | 0/25 |
The Safety population included all participants who received at least one dose of study drug.
| Age, Continuous(years) | Group 1: Setmelanotide 2-7 mg + Placebo for Moxifloxacin | Group 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for Moxifloxacin | Group 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mg | Total |
|---|---|---|---|---|
| Mean | 31.9 ± 6.47 | 36.1 ± 9.28 | 34.8 ± 8.60 | 34.2 ± 8.22 |
| Sex: Female, Male(Participants) | Group 1: Setmelanotide 2-7 mg + Placebo for Moxifloxacin | Group 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for Moxifloxacin | Group 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mg | Total |
|---|---|---|---|---|
| Female | 10 | 11 | 12 | 33 |
| Male | 18 | 13 | 13 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Setmelanotide 2-7 mg + Placebo for Moxifloxacin | Group 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for Moxifloxacin | Group 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 9 | 10 | 26 |
| Not Hispanic or Latino | 21 | 15 | 15 | 51 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: Setmelanotide 2-7 mg + Placebo for Moxifloxacin | Group 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for Moxifloxacin | Group 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 3 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 5 | 8 | 23 |
| White | 13 | 13 | 12 | 38 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 3 | 3 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Apr 2022, 8 months.
Results were first posted in May 2024, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →